CDKN2A and lymphoma: Acquired CDKN2A inactivation (gene deletion or hypermethylation resulting in decreased expression) at time of progression has been reported in studies of paired tumor analyses of other malignancies, including lymphoma, cervical cancer, and prostate cancer [19, 22, 46, 63].